Businesswire News Releases
May 20, 2024 04:43 ET
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio....
May 20, 2024 04:10 ET
Fluidra appoints Jaime Ramirez as Chief Executive Officer
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, appoints Jaime Ramirez as the company’s new Chief Executive Officer (CEO) effective 1 June 2024. The appointment follows a comprehensive succession planning process by the Board....
May 20, 2024 04:00 ET
Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM device that easily tracks real-time glucose readings to help improve diabetes management, and the Dexcom State of Type 2 Report. The report is a first-of-its-kind look at the Type 2 ...
May 20, 2024 03:00 ET
Battery Ventures Agrees to Acquire Medical and Industrial-Automation Company steute Technologies
Battery Ventures, a global, technology-focused investment firm, today announced it has agreed to acquire steute Technologies GmbH & Co. KG, a company with over 60 years of experience in manufacturing innovative technology solutions for the medical and industrial sectors....
May 20, 2024 02:00 ET
Astera Labs Extends Interoperability Leadership Driving Seamless PCIe 6.x Deployment
Astera Labs (Nasdaq: ALAB), a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced expanded PCIe® 6.x testing capabilities in its Cloud-Scale Interop Lab to enable seamless interoperability between
May 20, 2024 02:00 ET
Exchange Solutions Unveils Industry-First Generative AI Feature Enablement for a Loyalty Platform
Exchange Solutions, a leading provider of personalized loyalty solutions, proudly announces the launch of groundbreaking Generative AI features integrated into its loyalty platform. This innovative advancement, now available for use within the SaaS console, marks a significant milestone in enhancing marketer efficiency and effectiveness in loyalty program management....
May 20, 2024 02:00 ET
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the “Tender Offer”)....
May 20, 2024 00:21 ET
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Bau
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics today announced that China’s National Medical Products Administration (NMPA) has approved Zai Lab’s New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older. The World Health Organization considers Acinetobacter a top-priority pathogen worldwide that nee...
May 19, 2024 21:30 ET
Kirin Holdings will begin online sales of "Electric Salt Spoon", a spoon that uses electricity to enhance salty and umami taste*1, on May 20
Kirin Holdings Company, Limited (Kirin) will launch as a new business in the Health Science domain (Health Science business) a limited offering of 200 units of Electric Salt Spoon, which enhances the salty and umami taste of low-sodium foods with the power of electricity, on Monday, May 20, 2024 at its official online store (
May 19, 2024 17:17 ET
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significant (90% CI (Confidence Interval): -6, 36], p [1-sided]=0.10...
May 19, 2024 14:12 ET
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial that demonstrate the company’s lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF) over a 12-week period. The results, which also showed that ENV-101 had an acceptable tolerability profile, were presented for the first time today in a late-b...
May 19, 2024 12:15 ET
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA. Savara’s partner, Trillium Health LLC, presented a poster on the laboratory blood test...
May 19, 2024 07:50 ET
SharkNinja Announces David Beckham as Global Brand Ambassador for Ninja Brand
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, is pleased to announce that David Beckham has joined forces with the Ninja brand as a global brand ambassador. Known for his skills in the kitchen, passion for cooking and commitment to exceptional performance, Beckham will work closely with the Ninja team to buil...
May 18, 2024 13:28 ET
Dillard’s, Inc. Announces $0.25 Cash Dividend
Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”) announced that the Board of Directors declared a cash dividend of $0.25 per share on the Class A and Class B Common Stock of the Company. The dividend is payable August 5, 2024 to shareholders of record as of June 28, 2024....
May 18, 2024 08:30 ET
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are currently no treatments indicated to treat PBC-related pruritis. This data will be shared in an oral presentation during the Presidential...
May 18, 2024 07:00 ET
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI® (maralixibat) oral solution clinical studies and real-world settings in Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) were presented in oral and poster presentations during the meeting....
May 17, 2024 18:06 ET
Reser’s Fine Foods Announces Voluntary Recall of Single Batch of ALDI Macaroni 32 oz Salad With Use By Date of JUN/03/24 Due to Unlabeled Wheat Allergen
Reser’s Fine Foods is voluntarily recalling a single item with a specific use by date, produced at a regional facility and distributed to ALDI. The product is the Aldi Deli Macaroni Salad 32 oz, with a Use By Date of Jun/03/24 due to an incorrect label. The incorrect label does not include an allergen callout for wheat....
May 17, 2024 17:00 ET
The Lash Group Provides Substitute Notice of Data Incident to Affected Individuals
The Lash Group, LLC is issuing a substitute notice to individuals who may have been impacted by a data security incident. Lash Group’s parent company had previously announced a data security incident that has been fully contained....
May 17, 2024 16:46 ET
Barclays Bank PLC Announces Change to the Coupon Ex-Date for its iPath® Select MLP ETNs
Barclays Bank PLC (the “Issuer”) announced today that, effective Tuesday, May 28, 2024 (the “Effective Date”), the definition of Coupon Ex-Date for its iPath® Select MLP ETNs (the “ETNs”) will be amended. The ETNs trade on the CBOE BZX Exchange under the ticker symbol “ATMP”....
May 17, 2024 16:35 ET
DWS Municipal Income Trust and DWS Strategic Municipal Income Trust Announce Annual Meeting of Shareholders
DWS Municipal Income Trust (NYSE: KTF) and DWS Strategic Municipal Income Trust (NYSE: KSM) (each, a “Fund,” and, collectively, the “Funds”) announced that the Annual Meeting of Shareholders for each Fund will be held on September 20, 2024 at the offices of DWS Investment Management Americas, Inc., 100 Summer Street, Boston, Massachusetts. Holders of record of common shares and preferred shares of the Funds at the close of business on August 2, 2024 are entitled to vote at the Annual Meeting and any adjournments or postponements thereof....
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.